Drug Profile


Alternative Names: MBP 8298; SF328

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AutoImmune; University of Alberta
  • Developer BioMS Medical Corporation
  • Class Peptides
  • Mechanism of Action Immunosuppressants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Multiple sclerosis

Most Recent Events

  • 06 Jul 2010 BioMS Medical is now called Medwell Capital Corp.
  • 02 Sep 2009 BioMS Medical and Eli Lilly terminate their collaboration for dirucotide
  • 06 Oct 2008 BioMS receives a sixth positive review from the independent Data Safety Monitoring Board (DSMB) for the ongoing MINDSET-01 trial in relapsing-remitting Multiple sclerosis in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top